ClinicalTrials.gg
TerminatedNCT02598297ReTHINKUpdated Aug 16, 2019Results posted

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

A Phase 3 interventional study of Ruxolitinib and Ruxolitinib Placebo in Myelofibrosis With High Molecular Risk Mutations, sponsored by Novartis Pharmaceuticals. Terminated at 110 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Unresolvable inability to recruit the patients.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Enrollment
22nd of 50
49 · median 45
Started
2016
with 4 others
Phase 3
6 of 50
none open now
Registered
26th of 50
by date
Lead sponsor
11 of 50
Novartis Pharmaceuticals

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 22nd largest by enrollment, is one of 5 that started in 2016, is one of 6 in phase 3, and was the 26th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

Myelofibrosis patients with high molecular risk mutations have an intrinsically aggressive disease with increased risk of leukemic transformation and reduced overall survival. As there are no therapies currently established in the subset of high molecular risk patients with early myelofibrosis, the study aimed to evaluate ruxolitinib in this patient population.

03

Conditions studied

  • Myelofibrosis With High Molecular Risk Mutations

Browse trials for

Keywords

  • Early Myelofibrosis
  • high molecular risk mutations.
  • Ruxolitinib
  • INC424
  • High molecular risk mutations
  • HMR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of MF with bone marrow fibrosis of at least Grade 1; irrespective of JAK2 mutational status
  • Patients with at least one mutation in one of the five HMR genes (ASXL1, EZH2, SRSF2 and IDH1/2)
  • Patients with non-palpable spleen or spleen palpable ≤ 5 cm from the left costal margin to the point of greatest splenic protrusion
  • Patients with MF-7 score of ≤ 15, with each individual symptom score of ≤ 3

Exclusion criteria

Exclusion Criteria:

  • Patients with prior treatment with ruxolitinib or other JAK inhibitors.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Active comparator
    Ruxolitinib

    Two tablets of ruxolitinib 5 mg were administered orally twice per day.

    Drug: Ruxolitinib

  • Placebo comparator
    Ruxolitinib Placebo

    Two tablets of 5mg placebo were administered orally twice per day.

    Drug: Ruxolitinib Placebo

Interventions

  • 5 mg tablet for oral use

    Also known as: INC424

  • DrugRuxolitinib Placebo

    5 mg placebo tablet for oral use

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS-1)

    Progression free survival (PFS-1) from date of randomization until the occurrence of any of the criteria for disease progression: * Progressive splenomegaly * Circulating peripheral blast counts \> 10% * Leukemic transformation * Hb \< 10g/dl with absolute decrease of at least 3 g/dl from baseline * White blood cell (WBC) counts \> 25 x 103/ μL * MF-7 score ≥ 30 * Death from any cause

    Time frame: From randomization till disease progression (estimated to be assessed up 48 months)

Secondary outcomes

  1. Time to Primary Progression (TTP)

    TTP is defined as time from randomization until disease progression as defined for PFS-1 excluding death as an event.

    Time frame: From randomization till progression (estimated to be assessed up to 48 months)

  2. Percentage Change in Spleen Volume From Baseline

    Change in spleen volume (by MRI/CT) from baseline

    Time frame: From baseline and assessed on 12 week intervals until end of treatment (EOT)

  3. Percentage Change in Symptoms From Baseline Using MF-7

    Percentage change from Baseline in MF-7 total symptom score and 7 individual symptoms at each visit was summarized with descriptive statistics. For this scale, symptoms range from 0 to 10 for the severity experienced within the past 24 hours, with 0 being for absence of symptoms and 10 for worst imaginable symptoms.

    Time frame: From Baseline and assessed every 4 weeks until end of treatment

  4. Number of Participants With Specific Subscale Scores (From Baseline) Using EQ-5D

    EQ-ED5 profiles were summarized at baseline and at each scheduled assessment for each of the 5 dimensions separately (Mobility, self-care, usual activities, pain discomfort, anxiety/depression) Only participants with baseline score and at least one non-missing post-baseline score during the treatment period were included. Percentages were based on all these evaluable participants. The 5 scores for mobility, self-care, usual activities, pain/discomfort and anxiety/depression are all self-explanatory (eg "I have no problems walking" to "I am unable to walk"), except for the following overall health check, where 100 is the best of health, and 0 is the worst health.

    Time frame: From Baseline and assessed every 4 weeks until end of treatment

  5. Overall Survival

    To evaluate the effect of ruxolitinib on overall survival

    Time frame: Time from randomization to date of death due to any cause (estimated to be assessed up to 48 months).

  6. Plasma Ruxolitinib Concentrations

    Characterize pharmacokinetics (PK)by utilizing a population PK approach.

    Time frame: Week 12, Wk 48

  7. Progression Free Survival (PFS-2)

    PFS-2 assessed by 25% increase over new baseline of PFS-1 in any of the following: ● Progressive splenomegaly ● 25 % increase in MF-7 score with absolute score ≥ 30

    Time frame: From date of randomization until second disease progression or death, whichever comes first (estimated to be assessed up to 72 months)

  8. Quality-adjusted Life Years From Baseline

    EQ-5D-5L (EuroQol-5D-5L, is a standardized instrument for measuring health outcomes, is consists of a descriptive system and a visual analogue scale - scores can be summarized into a single index score that provides a simple measure of health for clinical and economic appraisal ) The EQ-5D-5L health states will be converted into index values (utilities) from which the QALY (Quality - adjusted life years) will be calculated. QALY will be summarized descriptively by treatment arm.

    Time frame: Change from Baseline compared with scheduled study visits at the following intervals every 4 weeks up to week 24, every 8 weeks up to Week 48, every 12 weeks past Wk 48 until End of treatment and 30 day follow up visit

  9. Time to First Progressive Splenomegaly (TTPS)

    Time to first progressive splenomegaly as determined by spleen volume (by Magnetic Resonance Imaging (MRI)/Computed Tomography (CT).

    Time frame: From randomization until earliest time to progressive splenomegaly (estimated to be assessed up to 48 months)

  10. Time to First Symptomatic Progression (TTSP)

    Time to first symptomatic progression as determined by Myelofibrosis 7 Item Symptom Scale (MF-7)

    Time frame: From randomization until symptomatic progression (MF-7)(estimated to be assessed up to 48 months)

07

Results

Posted Aug 16, 2019

Participant flow

Approximately 320 male or female adults (age 18 or over) with a confirmed diagnosis of MF were planned to be enrolled. The target population was not met due to early study termination. A total of 49 subjects were enrolled in the study, 25 in the ruxolitinib arm and 24 in the placebo arm.

Participant flow — Overall Study
MilestoneRuxolitinib (INC424)Ruxolitinib Placebo
Started2524
Not treted wit study drug10
Subjects followed for survival10
Completed00
Not completed2524
Withdrew: Study terminated by sponsor2123
Withdrew: Adverse event11
Withdrew: Physician decision10
Withdrew: Subject/guardian decision10
Withdrew: Followed for survival10

Outcome measures

PrimaryProgression Free Survival (PFS-1)

Progression free survival (PFS-1) from date of randomization until the occurrence of any of the criteria for disease progression: * Progressive splenomegaly * Circulating peripheral blast counts \> 10% * Leukemic transformation * Hb \< 10g/dl with absolute decrease of at least 3 g/dl from baseline * White blood cell (WBC) counts \> 25 x 103/ μL * MF-7 score ≥ 30 * Death from any cause

Time frame:
From randomization till disease progression (estimated to be assessed up 48 months)

No measurements were reported for this outcome.

SecondaryTime to Primary Progression (TTP)

TTP is defined as time from randomization until disease progression as defined for PFS-1 excluding death as an event.

Time frame:
From randomization till progression (estimated to be assessed up to 48 months)

No measurements were reported for this outcome.

SecondaryPercentage Change in Spleen Volume From Baseline

Change in spleen volume (by MRI/CT) from baseline

Time frame:
From baseline and assessed on 12 week intervals until end of treatment (EOT)
Reported as:
Mean · Percentage change from baseline
Percentage Change in Spleen Volume From Baseline
Percentage change from baselineRuxolitinib (INC424)Ruxolitinib Placebo
Week 12-10.8 ± 24.459.1 ± 12.34
Week 24-17.8 ± 18.8317.6 ± 17.78
Week 36-18.4 ± 31.6232.5 ± 18.81
Week 48-23.5 ± 10.57—
End of Treatment (EOT)-11.6 ± 8.0818.1 ± 18.58
SecondaryPercentage Change in Symptoms From Baseline Using MF-7

Percentage change from Baseline in MF-7 total symptom score and 7 individual symptoms at each visit was summarized with descriptive statistics. For this scale, symptoms range from 0 to 10 for the severity experienced within the past 24 hours, with 0 being for absence of symptoms and 10 for worst imaginable symptoms.

Time frame:
From Baseline and assessed every 4 weeks until end of treatment
Reported as:
Mean · Percentage change in scores
Percentage Change in Symptoms From Baseline Using MF-7
Percentage change in scoresRuxolitinib (INC424)Ruxolitinib Placebo
Total Score derived (TSD): Baseline (BL)6.6 ± 5.175.9 ± 5.56
TSD change from baseline @ W12-0.3 ± 4.450.5 ± 6.08
TSD change from baseline @ W240.5 ± 3.71-0.8 ± 6.44
TSD change from baseline @ W48-0.3 ± 3.06—
TSD change from BL @ EOT1.1 ± 4.403.3 ± 9.53
Tiredness: Baseline (BL)1.8 ± 1.451.5 ± 1.53
Tiredness: change from baseline @ W120.1 ± 1.470.4 ± 1.27
Tiredness: change from baseline @ W24-0.1 ± 0.761.1 ± 2.52
Tiredness: change from baseline @ W48-0.3 ± 0.58—
Tiredness change from BL @ EOT0.8 ± 1.321.1 ± 2.28
Filling up quickly when you eat (FUQWYE):BL1.0 ± 1.410.8 ± 1.27
FUQWYE: change from BL @W120.1 ± 1.49-0.1 ± 2.09
FUQWYE: change from BL @W24-0.2 ± 0.990.1 ± 1.17
FUQWYE: change from BL @W480.7 ± 1.15—
FUQWYE: change from BL @ EOT0.2 ± 1.080.3 ± 2.29
Abdominal discomfort (AD): BL0.7 ± 1.430.6 ± 1.10
Abdominal discomfort change from BL @W12-0.1 ± 1.66-0.1 ± 0.85
Abdominal discomfort change from BL @W240.0 ± 1.15-0.3 ± 0.71
Abdominal discomfort change from BL @W480.0 ± 0.00—
AD: change from BL @ EOT0.1 ± 0.920.3 ± 1.40
Night sweat (NS): Baseline (BL)0.7 ± 1.071.1 ± 1.45
Night sweat change from BL @W12-0.1 ± 0.71-0.3 ± 1.29
Night sweat change from BL @W240.5 ± 1.45-0.7 ± 1.41
Night sweat change from BL @W48-0.3 ± 0.58—
Night Sweat: change from BL @ EOT0.0 ± 0.850.3 ± 2.12
Itching (Pruritus):BL0.9 ± 1.420.6 ± 0.93
Itching (Pruritus): change from BL @W12-0.3 ± 0.670.1 ± 1.45
Itching (Pruritus): change from BL @W240.4 ± 0.77-0.3 ± 1.22
Itching (Pruritus): change from BL @W48-1.0 ± 1.73—
Itching: change from BL @ EOT0.1 ± 1.030.4 ± 1.75
Bone Pain: BL0.9 ± 1.350.9 ± 1.33
Bone Pain: change from BL @W12-0.4 ± 1.010.3 ± 1.56
Bone Pain: change from BL @W24-0.2 ± 1.17-0.8 ± 1.79
Bone Pain: change from BL @W480.7 ± 1.15—
Bone Pain: change from BL @ EOT0.1 ± 0.960.6 ± 1.50
Pain under ribs on left side (PUROLS): BL0.7 ± 1.180.4 ± 0.82
PUROLS: change from BL @W120.4 ± 1.010.1 ± 0.76
PUROLS: change from BL @W240.0 ± 0.410.1 ± 1.17
PUROLS: change from BL @W480.0 ± 0.00—
PUROLS: change from BL @ EOT-0.2 ± 0.680.3 ± 1.00
SecondaryNumber of Participants With Specific Subscale Scores (From Baseline) Using EQ-5D

EQ-ED5 profiles were summarized at baseline and at each scheduled assessment for each of the 5 dimensions separately (Mobility, self-care, usual activities, pain discomfort, anxiety/depression) Only participants with baseline score and at least one non-missing post-baseline score during the treatment period were included. Percentages were based on all these evaluable participants. The 5 scores for mobility, self-care, usual activities, pain/discomfort and anxiety/depression are all self-explanatory (eg "I have no problems walking" to "I am unable to walk"), except for the following overall health check, where 100 is the best of health, and 0 is the worst health.

Time frame:
From Baseline and assessed every 4 weeks until end of treatment
Reported as:
Count of participants · Participants
Number of Participants With Specific Subscale Scores (From Baseline) Using EQ-5D
ParticipantsRuxolitinib (INC424)Ruxolitinib Placebo
Mobility- Baseline: No problem1718
Mobility- Baseline: Slight problems45
Mobility- Baseline: Moderate problems11
Mobility- Baseline: Extreme problems10
Mobility - Week 4:No prob.1714
Mobility - Week 4: Slight problems47
Mobility - Week 4: Moderate problems12
Mobility - Week 8: No problem1715
Mobility - Week 8: Slight problems36
Mobility - Week 8: Moderate problems01
Mobility - Week 12: No problem1512
Mobility - Week 12: Slight problems46
Mobility - Week 12: Moderate problems02
Mobility - Week 16: No problem1210
Mobility - Week 16: Slight problems27
Mobility - Week 16: Moderate problems10
Mobility - Week 20: No problem125
Mobility - Week 20: Slight problems26
Mobility - Week 24: No problem125
Mobility - Week 24: Slight problems13
Mobility - Week 24: Moderate problems01
Mobility - Week 32: No problem81
Mobility - Week 32: Slight problems01
Mobility - Week 32: Moderate problems10
Mobility - Week 40: No problem50
Mobility - Week 40: Slight problems10
Mobility - Week 48: No problem20
Mobility - Week 48: Slight problems10
Mobility - EOT: No problem1112
Mobility - EOT: Slight problems43
Mobility - EOT: Moderate problems01
Mobility- 30 day safety FU: No problem23
Mobility- 30 day safety FU: Slight problems10
Self-care - Baseline: No problem2322
Self-care - Baseline: Slight problems02
Self-care - Week 4: No problem2120
Self-care - Week 4: Slight problems03
Self-care - Week 4: Moderate problems10
Self-care - Week 8: No problem1921
Self-care - Week 8: Slight problems11
Self-care - Week 12: No problem1719
Self-care - Week 12: Slight problems11
Self-care - Week 12: Moderate problems10
Self-care - Week 16: No problem1516
Self-care - Week 16: Slight problems01
Self-care - Week 20: No problem1411
Self-care - Week 24: No problem129
Self-care - Week 24: Slight problems10
Self-care - Week 32: No problem82
Self-care - Week 32: Slight problems10
Self-care - Week 40: No problem50
Self-care - Week 40: Slight problems10
Self-care - Week 48: No problem30
Self-care - EOT: No problem1415
Self-care - EOT: Slight problems11
Self-care - 30 day Safety FU: No problem33
Usual activities -Baseline: No problem1821
Usual activities -Baseline: Slight problems43
Usual activities - Baseline: Moderate problems10
Usual activities - Week 4: No problem2018
Usual activities - Week 4: Slight problems14
Usual activities - Week 4: Moderate problems10
Usual activities - Week 4: Severe problems01
Usual activities - Week 8: No problem2018
Usual activities - Week 8: Slight problems03
Usual activities - Week 8: Moderate problems01
Usual activities - Week 12: No problem1616
Usual activities - Week 12: Slight problems33
Usual activities - Week 12: Moderate problems01
Usual activities - Week 16: No problem1314
Usual activities - Week 16: Slight problems23
Usual activities - Week 20: No problem139
Usual activities - Week 20: Slight problems12
Usual activities - Week 24: No problem129
Usual activities - Week 24: Slight problems10
Usual activities - Week 32: No problem82
Usual activities - Week 32: Slight problems10
Usual activities - Week 40: No problem50
Usual activities - Week 40: Slight problems10
Usual activities - Week 48: No problem30
Usual activities - EOT: No problem1213
Usual activities -EOT: Slight problems33
Usual activities - 30 day Safety FU: No problem23
Usual activities - 30 say Safety FU: Slight probs10
Pain/Discomfort - Baseline: No problem1311
Pain/Discomfort - Baseline: Slight problems812
Pain/Discomfort - Baseline: Moderate problems21
Pain/Discomfort - Week 4: No problem1115
Pain/Discomfort - Week 4: Slight problems106
Pain/Discomfort - Week 4: Moderate problems12
Pain/Discomfort - Week 8: No problem1413
Pain/Discomfort - Week 8: Slight problems57
Pain/Discomfort - Week 8: Moderate problems12
Pain/Discomfort - Week 12: No problem1210
Pain/Discomfort - Week 12: Slight problems76
Pain/Discomfort - Week 12: Moderate problems04
Pain/Discomfort - Week 16: No problem911
Pain/Discomfort - WK16: Slight problems63
Pain/Discomfort - WK16: Moderate problems03
Pain/Discomfort - WK20: No problem88
Pain/Discomfort - WK20: Slight problems63
Pain/Discomfort - WK24: No problem97
Pain/Discomfort - WK24: Slight problems42
Pain/Discomfort - WK32: No problem72
Pain/Discomfort - WK32: Slight problems20
Pain/Discomfort - WK40: No problem40
Pain/Discomfort - WK40: Slight problems20
Pain/Discomfort - WK48: No problem30
Pain/Discomfort - EOT: No problem810
Pain/Discomfort - EOT: Slight problems73
Pain/Discomfort - EOT: Moderate problems03
Pain/Discomfort - 30 day Safety FU: No problem12
Pain/Discomfort - 30 day safety FU: Slight probs20
Pain/Discomfort - 30 day Safety FU: Moderate probs01
Anxiety/Depression - Baseline: No problem1418
Anxiety/Depression - Baseline: Slight problems63
Anxiety/Depression - Baseline: Moderate problems33
Anxiety/Depression - WK4: No problem1315
Anxiety/Depression - WK4: Slight problems76
Anxiety/Depression - WK4: Moderate problems22
Anxiety/Depression - WK8: No problem1116
Anxiety/Depression - WK8: Slight problems82
Anxiety/Depression - WK8: Moderate problems14
Anxiety/Depression - WK12: No problem813
Anxiety/Depression - WK12: Slight problems103
Anxiety/Depression -WK12: Moderate problems14
Anxiety/Depression - WK16: No problem1010
Anxiety/Depression - WK16: Slight problems55
Anxiety/Depression - WK16: Moderate problems02
Anxiety/Depression -WK20: No problem108
Anxiety/Depression - WK20: Slight problems43
Anxiety/Depression - WK24: No problem117
Anxiety/Depression - WK24: Slight problems22
Anxiety/Depression - WK32: No problem72
Anxiety/Depression - WK32: Slight problems20
Anxiety/Depression - WK40: No problem50
Anxiety/Depression - WK40: Slight problems10
Anxiety/Depression - WK48: No problem30
Anxiety/Depression - EOT: No problem1112
Anxiety/Depression - EOT: Slight probs43
Anxiety/Depression - EOT: Moderate probs01
Anxiety/Depression - 30 day Safety FU: No probs22
Anxiety/Depression-30 day Safety FU: Slight probs10
Anxiety/Depression-30 day Safety FU: Severe probs01
SecondaryOverall Survival

To evaluate the effect of ruxolitinib on overall survival

Time frame:
Time from randomization to date of death due to any cause (estimated to be assessed up to 48 months).

No measurements were reported for this outcome.

SecondaryPlasma Ruxolitinib Concentrations

Characterize pharmacokinetics (PK)by utilizing a population PK approach.

Time frame:
Week 12, Wk 48

No measurements were reported for this outcome.

SecondaryProgression Free Survival (PFS-2)

PFS-2 assessed by 25% increase over new baseline of PFS-1 in any of the following: ● Progressive splenomegaly ● 25 % increase in MF-7 score with absolute score ≥ 30

Time frame:
From date of randomization until second disease progression or death, whichever comes first (estimated to be assessed up to 72 months)

No measurements were reported for this outcome.

SecondaryQuality-adjusted Life Years From Baseline

EQ-5D-5L (EuroQol-5D-5L, is a standardized instrument for measuring health outcomes, is consists of a descriptive system and a visual analogue scale - scores can be summarized into a single index score that provides a simple measure of health for clinical and economic appraisal ) The EQ-5D-5L health states will be converted into index values (utilities) from which the QALY (Quality - adjusted life years) will be calculated. QALY will be summarized descriptively by treatment arm.

Time frame:
Change from Baseline compared with scheduled study visits at the following intervals every 4 weeks up to week 24, every 8 weeks up to Week 48, every 12 weeks past Wk 48 until End of treatment and 30 day follow up visit

No measurements were reported for this outcome.

SecondaryTime to First Progressive Splenomegaly (TTPS)

Time to first progressive splenomegaly as determined by spleen volume (by Magnetic Resonance Imaging (MRI)/Computed Tomography (CT).

Time frame:
From randomization until earliest time to progressive splenomegaly (estimated to be assessed up to 48 months)

No measurements were reported for this outcome.

SecondaryTime to First Symptomatic Progression (TTSP)

Time to first symptomatic progression as determined by Myelofibrosis 7 Item Symptom Scale (MF-7)

Time frame:
From randomization until symptomatic progression (MF-7)(estimated to be assessed up to 48 months)

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events and serious adverse events were collected for the maximum actual duration of treatment exposure and follow up for a participant per the protocol for approximately up to approx. 55.1 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib (INC424)0/24 (0%)2/24 (8.3%)17/24 (70.8%)
Ruxolitinib Placebo0/24 (0%)1/24 (4.2%)11/24 (45.8%)
Most frequent serious events
Most frequent serious events
EventRuxolitinib (INC424)Ruxolitinib Placebo
Tendon ruptureInjury, poisoning and procedural complications1/240/24
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/240/24
PneumonitisRespiratory, thoracic and mediastinal disorders0/241/24
Most frequent other events
Showing 10 of 12
Most frequent other events
EventRuxolitinib (INC424)Ruxolitinib Placebo
AnaemiaBlood and lymphatic system disorders7/246/24
FatigueGeneral disorders3/244/24
NasopharyngitisInfections and infestations4/240/24
Upper respiratory tract infectionInfections and infestations3/240/24
CoughRespiratory, thoracic and mediastinal disorders3/240/24
PruritusSkin and subcutaneous tissue disorders0/243/24
HypertensionVascular disorders3/243/24
ThrombocytopeniaBlood and lymphatic system disorders0/242/24
PyrexiaGeneral disorders2/240/24
Respiratory tract infectionInfections and infestations2/240/24

Baseline characteristics

The Full Analysis Set (FAS) included all subjects who were randomized to a study treatment.

Age, Continuous
Age, Continuous(Years)Ruxolitinib (INC424)Ruxolitinib PlaceboTotal
Mean59.0 ± 14.2367.4 ± 7.7263.1 ± 12.17
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib (INC424)Ruxolitinib PlaceboTotal
Female12719
Male131730
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ruxolitinib (INC424)Ruxolitinib PlaceboTotal
Caucasian192342
Asian415
Other101
Missing101
08

Study locations

110 sites
  • Novartis Investigative Site
    Concord NSW, New South Wales 2139, Australia
  • Novartis Investigative Site
    Liverpool, New South Wales 2170, Australia
  • Novartis Investigative Site
    Wooloongabba, Queensland 4102, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    Vienna, A-1090, Austria
  • Novartis Investigative Site
    Antwerpen, 2060, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Sao Paulo, SP 05403 000, Brazil
  • Novartis Investigative Site
    São Paulo, SP 08270-070, Brazil
  • Novartis Investigative Site
    Sao Paulo, 01236030, Brazil
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Aalborg, DK 9000, Denmark
  • Novartis Investigative Site
    Herlev, DK 2730, Denmark
  • Novartis Investigative Site
    Bayonne, Bayonne Cedex 64109, France
  • Novartis Investigative Site
    Angers Cedex 1, 49033, France
  • Novartis Investigative Site
    Brest, 29200, France
  • Novartis Investigative Site
    Chambéry Cedex, 73011, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Lille Cedex, 59037, France
  • Novartis Investigative Site
    Nice Cedex, 06202, France
  • Novartis Investigative Site
    Rouen Cedex 1, 76038, France
  • Novartis Investigative Site
    Vandoeuvre Les Nancy, 54511, France
  • Novartis Investigative Site
    Luebeck, Schleswig-holstein 23563, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Bochum, 44787, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    Chemnitz, 09113, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Halle S, 06120, Germany
  • Novartis Investigative Site
    Heilbronn, 74072, Germany
  • Novartis Investigative Site
    Koeln, 50671, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Muenchen, 81241, Germany
  • Novartis Investigative Site
    Nordhorn, 48527, Germany
  • Novartis Investigative Site
    Rostock, 18057, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Athens, GR 115 27, Greece
  • Novartis Investigative Site
    Thessaloniki, GR 570 10, Greece
  • Novartis Investigative Site
    Athens, 106 76, Greece
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Patras, 265 00, Greece
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Budapest, H 1083, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Kaposvar, 7400, Hungary
  • Novartis Investigative Site
    Afula, 1834111, Israel
  • Novartis Investigative Site
    Haifa, 3525408, Israel
  • Novartis Investigative Site
    Jerusalem, 91120, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Zrifin, 70300, Israel
  • Novartis Investigative Site
    Bari, BA 70124, Italy
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    Catania, CT 95123, Italy
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Roma, Lazio 00168, Italy
  • Novartis Investigative Site
    Milano, MI 20122, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Reggio Emilia, RE 42123, Italy
  • Novartis Investigative Site
    Orbassano, TO 10043, Italy
  • Novartis Investigative Site
    Terni, TR 05100, Italy
  • Novartis Investigative Site
    Varese, VA 21100, Italy
  • Novartis Investigative Site
    Nagoya, Aichi 453-8511, Japan
  • Novartis Investigative Site
    Fukuoka city, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Maebashi city, Gunma 371 8511, Japan
  • Novartis Investigative Site
    Kobe-city, Hyogo 650-0047, Japan
  • Novartis Investigative Site
    Isehara, Kanagawa 259-1193, Japan
  • Novartis Investigative Site
    Suita city, Osaka 565 0871, Japan
  • Novartis Investigative Site
    Bunkyo ku, Tokyo 113-8431, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Novartis Investigative Site
    Chuo-city, Yamanashi 409-3898, Japan
  • Novartis Investigative Site
    Osaka, 545-8586, Japan
  • Novartis Investigative Site
    Bergen, N-5021, Norway
  • Novartis Investigative Site
    Loerenskog, NO 1478, Norway
  • Novartis Investigative Site
    Lodz, 93-513, Poland
  • Novartis Investigative Site
    Torun, 87 100, Poland
  • Novartis Investigative Site
    Wroclaw, 50 367, Poland
  • Novartis Investigative Site
    Faro, 8000-386, Portugal
  • Novartis Investigative Site
    Porto, 4200-072, Portugal
  • Novartis Investigative Site
    Moscow, 129110, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 191024, Russian Federation
  • Novartis Investigative Site
    St Petersburg, 194044, Russian Federation
  • Novartis Investigative Site
    Singapore, 119228, Singapore
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Cadiz, Andalucia 11009, Spain
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Göteborg, SE-413 45, Sweden
  • Novartis Investigative Site
    Huddinge, SE-14186, Sweden
  • Novartis Investigative Site
    Lund, SE-221 85, Sweden
  • Novartis Investigative Site
    Uddevalla, 451 80, Sweden
  • Novartis Investigative Site
    Basel, 4031, Switzerland
  • Novartis Investigative Site
    St Gallen, 9001, Switzerland
  • Novartis Investigative Site
    Zuerich, 8091, Switzerland
  • Novartis Investigative Site
    Putzu City, Chiayi Hsien 61363, Taiwan
  • Novartis Investigative Site
    Kaohsiung City, 83301, Taiwan
  • Novartis Investigative Site
    Taipei, 10002, Taiwan

Showing the first 100 of 110 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Oct 2017, 20 months.

Results were first posted in Aug 2019, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2015
First posted
Nov 5, 2015
StartActual
Feb 3, 2016
Primary completionActual
Oct 23, 2017
CompletionActual
Oct 23, 2017
Results first posted
Aug 16, 2019
Last update
Aug 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02598297
Responsible party
Sponsor
First posted
Nov 5, 2015
Start date
Feb 3, 2016
Primary completion
Oct 23, 2017
Completion
Oct 23, 2017
Results posted
Aug 16, 2019
Last update
Aug 16, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion